Bacterial attachment as a predictor of renal abnormalities in boys with urinary tract infection.
The development of renal scarring was analyzed prospectively in 241 boys with their first known episode of symptomatic urinary tract infection (140 acute pyelonephritis, 61 acute cystitis, and 40 nonspecific). Of 197 boys undergoing urography, 22 (11%) had scars; 20 were in the pyelonephritis group. Vesicoureteral reflux occurred in 81% of those with scarring, compared with 20% of those without scarring. The bacteria causing the first episode of urinary tract infection in each patient were saved, and Escherichia coli organisms were characterized for the expression of both galactose-alpha (1----4)galactose-beta (Gal-Gal)-specific adhesins and pap homologous DNA. Scarring occurred in 41% and other renal abnormalities in 11% of boys infected with bacteria that did not bind Gal-Gal (Gal-Gal negative), compared with 5% and 1%, respectively, in those infected with Gal-Gal-binding strains (Gal-Gal-positive) (relative risk 8.3; 95% confidence limits 3.3 to 20.4; p less than 0.001). That boys infected with Gal-Gal-negative strains more often had reflux did not explain the increased risk for renal scarring in this group. The possibility that the phenotypically negative strains could be induced to express Gal-Gal adhesions in vivo was excluded by dot blot analysis, which showed the absence of pap homologous DNA in all but one of the Gal-Gal-negative strains. The results suggest that the absence of Gal-Gal-specific adhesins in E. coli can be used as an indicator of risk for renal scarring and the need for radiologic examination.
de Man
P
P
Department of Clinical Immunology, University of Göteborg, Sweden.
Cläeson
I
I
Johanson
I M
IM
Jodal
U
U
Svanborg Edén
C
C
D000293:Adolescent; D001422:Bacterial Adhesion; D002648:Child; D002675:Child, Preschool; D002921:Cicatrix / Q000209:etiology*; D003556:Cystitis / Q000150:complications / Q000188:drug therapy / Q000382:microbiology*; D004926:Escherichia coli / Q000472:pathogenicity*; D005690:Galactose / Q000378:metabolism; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007674:Kidney Diseases / Q000209:etiology; D008297:Male; D011446:Prospective Studies; D011704:Pyelonephritis / Q000150:complications / Q000188:drug therapy / Q000382:microbiology*; D012307:Risk Factors; D014552:Urinary Tract Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology*; D014567:Urography
D005690:Galactose